According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
5
Jan, 2018
AI early diagnosis could save heart and cancer patients By Pallab GhoshScience correspondent, BBC News 2 January 2018 Original Article: http://www.bbc.com/news/health-42357257 Researchers at an Oxford hospital have developed artificial intelligence (AI) that can diagnose scans for heart disease and lung…
READ MORE
29
Nov, 2016
A supramolecular indicator displacement assay for acetyl amantadine, a proxy biomarker for spermidine/spermine N1-acetyltransferase (SSAT) activity Introduction Cancer is a leading cause of death worldwide.1 The number of new cancer cases is expected to increase 40% in the next 15 years in Canada due to an aging and growing population.2 Lung cancer is the most commonly diagnosed in this country (excluding nonmelanoma skin cancers) and accounts for 14% of all…
READ MOREMarch 14, 2019
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “This is our follow up publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides further scientific […]
BioMark has been funded by various government agencies including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta since 2006. New research applications to Genome Canada and Genome BC Strategic Innovation Program were submitted in 2017 reviewed by peer groups. Now BioMark is collaborating with Bio banks across Canada to expand our metabolomics study.